Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: Audio-slides
Published: 11 February 2020| Version 1 | DOI: 10.17632/cj98sw6zr5.1
Contributors:
Pierre Van Damme, Geert Leroux-Roels, Corinne Vandermeulen, Iris De Ryck, Annaelisa Tasciotti, Marie Dozot, Luca Moraschini, Marco Testa, Ashwani Kumar AroraDescription
These audio-slides support the published article Pierre Van Damme, Geert Leroux-Roels, Corinne Vandermeulen, Iris De Ryck, Annaelisa Tasciotti, Marie Dozot, Luca Moraschini, Marco Testa, Ashwani Kumar Arora. Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine. Vaccine. 2019;37(23):3113-3122. In this article, we provide evidence that an investigational non-typeable Haemophilus influenzae and Moraxella catarrhalis (NTHi-Mcat) protein vaccine has an acceptable safety and reactogenicity profile and good immunogenicity in older adults with smoking history.
Files
Institutions
- GlaxoSmithKline Biologicals SA
Categories
Vaccine, Chronic Obstructive Pulmonary Disease, Immunogenicity, Safety, Clinical Trial Results, Haemophilus influenzae, Exacerbation (Medicine)